Purpose : Nonsteroidal antiinflammatory drugs (NSAIDs) are reported to penetrate the vitreous and lower basal prostaglandin E2 level. We investigated the functional and morphological changes in patients treated with NSAIDs before vitrectomy for macular pucker. Methods : A prospective, investigator-masked, randomized study was performed in 64 patients scheduled to undergo 25-gauge vitrectomy. The patients were randomized 1:1:1:1 to receive indomethacin 0.5%, bromfenac 0.09%, nepafenac 0.1%, or placebo three times a day one week before surgery. Main outcome measures were best-corrected visual acuity (BCVA) and central macular thickness (CMT) findings. Results : Mean BCVA improvement was 0.24 ± 0.15 LogMAR for indomethacin, 0.26 ± 0.13 LogMAR for bromfenac, 0.23 ± 0.1 LogMAR for nepafenac, and 0.23 ± 0.1 LogMAR for placebo (P = 0.87). Mean CMT reduction was 50.2 ± 85 µm for indomethacin, 122.4 ± 63 µm for bromfenac, 65.6 ± 100 µm for nepafenac, and 117.2 ± 164.3 for placebo (P = 0.3). No statistical differences among the different NSAID groups were noticed in either BCVA or CMT. Conclusions : Despite the antiinflammatory activity of the NSAIDs in the vitreous, no functional or morphological improvements were observed after macular pucker surgery.

Functional and Morphological Changes Following Macular Pucker Surgery After Topical Administration of Indomethacin 0.5%, Bromfenac 0.09%, Nepafenac 0.1%, or Placebo

TURANO, Raffaele;RUSSO, Andrea;GAMBICORTI, Elena;CANCARINI, Anna;DUSE, SARAH;SEMERARO, Francesco
2016-01-01

Abstract

Purpose : Nonsteroidal antiinflammatory drugs (NSAIDs) are reported to penetrate the vitreous and lower basal prostaglandin E2 level. We investigated the functional and morphological changes in patients treated with NSAIDs before vitrectomy for macular pucker. Methods : A prospective, investigator-masked, randomized study was performed in 64 patients scheduled to undergo 25-gauge vitrectomy. The patients were randomized 1:1:1:1 to receive indomethacin 0.5%, bromfenac 0.09%, nepafenac 0.1%, or placebo three times a day one week before surgery. Main outcome measures were best-corrected visual acuity (BCVA) and central macular thickness (CMT) findings. Results : Mean BCVA improvement was 0.24 ± 0.15 LogMAR for indomethacin, 0.26 ± 0.13 LogMAR for bromfenac, 0.23 ± 0.1 LogMAR for nepafenac, and 0.23 ± 0.1 LogMAR for placebo (P = 0.87). Mean CMT reduction was 50.2 ± 85 µm for indomethacin, 122.4 ± 63 µm for bromfenac, 65.6 ± 100 µm for nepafenac, and 117.2 ± 164.3 for placebo (P = 0.3). No statistical differences among the different NSAID groups were noticed in either BCVA or CMT. Conclusions : Despite the antiinflammatory activity of the NSAIDs in the vitreous, no functional or morphological improvements were observed after macular pucker surgery.
File in questo prodotto:
File Dimensione Formato  
arvo 2016 fans pucker.pdf

gestori archivio

Descrizione: ARVO 2016 fans and vitreous
Tipologia: Abstract
Licenza: DRM non definito
Dimensione 233.87 kB
Formato Adobe PDF
233.87 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11379/484422
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 0
social impact